Dynogen Pharmaceuticals, Inc.'s Oral Prokinetic Drug, DDP733, Shown to Reduce Reflux in Phase 1B Study
10/15/2007 11:10:17 AM
WALTHAM, Mass.--(BUSINESS WIRE)--Dynogen Pharmaceuticals, Inc. announced the presentation of its positive Phase 1b trial results for its DDP733 (pumosetrag) nocturnal gastroesophageal reflux disease (NGERD) program at the American College of Gastroenterology Annual Scientific Meeting (ACG) in Philadelphia, PA. The randomized, double-blind, placebo-controlled study demonstrated proof-of-concept and overall safety and tolerability of DDP733 in reducing reflux events. The ACG abstract was authored by researchers from the Mayo Clinic and Dynogen. The DDP733 results were presented on October 14, 2007 during a poster session.